{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T21:27:14Z","timestamp":1776115634278,"version":"3.50.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BLCA) is a malignant tumor characterized by pronounced molecular and immunological heterogeneity. Despite continuous advances in immunotherapy and targeted treatment, clinical outcomes vary substantially, and effective molecular stratification and predictive biomarkers remain lacking. The SWI\/SNF chromatin-remodeling complex regulates chromatin accessibility and gene transcription through ATP-dependent mechanisms and frequently harbors mutations across multiple cancer types. However, whether SWI\/SNF-related molecular patterns can be leveraged for clinically meaningful stratification and therapeutic prediction in BLCA remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated the TCGA-BLCA dataset, the IMvigor210 immunotherapy cohort, GEO datasets, and an independently sequenced Xiangya RNA cohort to comprehensively analyze SWI\/SNF-related genes. Unsupervised clustering was applied to construct SWI\/SNF molecular subtypes, and a quantitative scoring system, SWI_SNF_Score, was established based on differentially expressed and prognostically relevant genes. Using transcriptomic profiling across multiple cohorts and bioinformatics approaches, we assessed the relationships between SWI_SNF_Score, molecular subtypes, clinical outcomes, characteristics of the tumor immune microenvironment, and therapeutic responses, followed by validation in independent cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two distinct SWI\/SNF-associated molecular subtypes were identified across integrated transcriptomic datasets. Based on differentially expressed genes, we constructed the SWI_SNF_Score to quantitatively represent SWI\/SNF-related molecular and immune features in BLCA. A high SWI_SNF_Score was significantly associated with the basal subtype, enhanced stromal and immune activation, frequent RB1\/TP53 co-mutations, and unfavorable prognosis. In contrast, a low SWI_SNF_Score displayed luminal differentiation features, enrichment of FGFR3\/KDM6A mutations, and favorable survival outcomes. The SWI_SNF_Score accurately predicted classical molecular subtypes, TME phenotypes, and multiple treatment sensitivities and was independently validated in both the Xiangya and IMvigor210 immunotherapy cohorts. Notably, the score exhibited distinct predictive value across different immune phenotypes, enabling more precise stratification of potentially responsive populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The SWI_SNF_Score enables quantitative evaluation of molecular and immune heterogeneity in bladder cancer and provides a clinically relevant framework for prognostic stratification and immunotherapy response prediction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1774929","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:57:06Z","timestamp":1771397826000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["SWI\/SNF-associated molecular subtypes reshape tumor microenvironmental features and inform precision therapeutic strategies in bladder cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Tiezheng","family":"Qi","sequence":"first","affiliation":[{"name":"Department of General Surgery, Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]},{"name":"Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqi","family":"Yang","sequence":"additional","affiliation":[{"name":"Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingshan","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Urology, Hunan Provincial People\u2019s Hospital the First Affiliated Hospital of Hunan Normal University","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China","place":["Changsha, Hunan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S1470-2045(19)30522-4","article-title":"Erdafitinib for advanced urothelial carcinoma","volume":"20","author":"Burki","year":"2019","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2207155","DOI":"10.1002\/advs.202207155","article-title":"BCAT2 shapes a noninflamed tumor microenvironment and induces resistance to anti-PD-1\/PD-L1 immunotherapy by negatively regulating proinflammatory chemokines and anticancer immunity","volume":"10","author":"Cai","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e20628","article-title":"CDKN2A\/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach","volume":"37","author":"Giusti","year":"2019","journal-title":"J. OF Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: A real-world experience","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bph.16257","article-title":"Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer","volume":"181","author":"Gy\u0151rffy","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"215924","DOI":"10.1016\/j.canlet.2022.215924","article-title":"Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal\/squamous-subtype muscle-invasive bladder cancer","volume":"550","author":"He","year":"2022","journal-title":"Cancer Lett."},{"key":"B14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12916-021-02163-6","article-title":"5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer","volume":"19","author":"Hu","year":"2021","journal-title":"BMC Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.7150\/thno.53649","article-title":"Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer","volume":"11","author":"Hu","year":"2021","journal-title":"Theranostics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100785","article-title":"Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study","volume":"3","author":"Hu","year":"2022","journal-title":"Cell Rep. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e70063","DOI":"10.1002\/imt2.70063","article-title":"Neoadjuvant immunotherapy driven bladder preservation for muscle invasive bladder cancer","volume":"4","author":"Hu","year":"2025","journal-title":"IMETA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e70063","DOI":"10.1002\/imt2.70033","article-title":"Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study","volume":"4","author":"Hu","year":"2025","journal-title":"IMETA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ccell.2023.03.021","article-title":"Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression","volume":"41","author":"Jana","year":"2023","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2300110","DOI":"10.1002\/advs.202300110","article-title":"S100A5 attenuates efficiency of anti-PD-L1\/PD-1 immunotherapy by inhibiting CD8(+) T cell-mediated anti-cancer immunity in bladder carcinoma","volume":"10","author":"Li","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101059","DOI":"10.1016\/j.drup.2024.101059","article-title":"Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer","volume":"73","author":"Li","year":"2024","journal-title":"Drug Resist. Update"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1097\/JS9.0000000000001516","article-title":"Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study","volume":"110","author":"Li","year":"2024","journal-title":"Int. J. Surg."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2303230","DOI":"10.1002\/advs.202303230","article-title":"Cancer-associated fibroblast-induced remodeling of tumor microenvironment in recurrent bladder cancer","volume":"10","author":"Liang","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791924","article-title":"A novel TGF-\u03b2 Risk score predicts the clinical outcomes and tumour microenvironment phenotypes in bladder cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.ccell.2022.11.005","article-title":"Interferon-dependent SLC14A1(+) cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer","volume":"40","author":"Ma","year":"2022","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","article-title":"Urine biomarkers in bladder cancer - current status and future perspectives","volume":"20","author":"Maas","year":"2023","journal-title":"Nat. Rev. Urol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41573-024-00978-5","article-title":"Chromatin remodellers as therapeutic targets","volume":"23","author":"Malone","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/djx243","article-title":"Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas","volume":"110","author":"Mo","year":"2018","journal-title":"J. Natl. Cancer Inst"},{"key":"B35","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.euf.2019.10.016","article-title":"Predicting response to neoadjuvant chemotherapy in bladder cancer","volume":"6","author":"Motterle","year":"2020","journal-title":"Eur. Urol Focus"},{"key":"B36","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41586-024-07250-1","article-title":"Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI\/SNF","volume":"628","author":"Radko-Juettner","year":"2024","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"244ra91","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.semdp.2020.05.005","article-title":"SWI\/SNF complex-deficient soft tissue neoplasms: An update","volume":"38","author":"Schaefer","year":"2021","journal-title":"Semin. Diagn. Pathol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41577-023-00884-8","article-title":"Localization, tissue biology and T cell state - implications for cancer immunotherapy","volume":"23","author":"Schenkel","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sj\u00f6dahl","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.1038\/s41467-021-26421-6","article-title":"Pparg signaling controls bladder cancer subtype and immune exclusion","volume":"12","author":"Tate","year":"2021","journal-title":"Nat. Commun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nrc3068","article-title":"SWI\/SNF nucleosome remodellers and cancer","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2020.04.023","article-title":"Deep learning predicts molecular subtype of muscle-invasive bladder cancer from conventional histopathological slides","volume":"78","author":"Woerl","year":"2020","journal-title":"Eur. Urol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-022-01291-7","article-title":"Integrated proteogenomic characterization of urothelial carcinoma of the bladder","volume":"15","author":"Xu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12885-025-13698-9","article-title":"Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer","volume":"25","author":"Yan","year":"2025","journal-title":"BMC Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000651","article-title":"Stromal LAG-3(+) cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture","volume":"8","author":"Zeng","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40779-024-00569-w","article-title":"Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021","volume":"11","author":"Zi","year":"2024","journal-title":"Mil Med. Res."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1774929\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:32:49Z","timestamp":1771932769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1774929\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":52,"alternative-id":["10.3389\/fcimb.2026.1774929"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1774929","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1774929"}}